Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin

Epilepsy Research

Volumn 102, Issue 1-2, 2012, Pages 13-22

  Kleinman, Nathan L ^a   Sadosky, Alesia ^b   Seid, Jaren ^a   Martin, Roy C ^c   Labiner, David M ^d  

^a Human Capital Management Services   (United States)

^b PFIZER INC   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Adherence; Costs; Gabapentin; Partial onset seizures; Pregabalin; Work absence

Indexed keywords

ACETAZOLAMIDE; CARBAMAZEPINE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LORAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RUFINAMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENTEEISM; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISABILITY; DRUG COST; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; EMPLOYEE; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICAL LEAVE; PARTIAL ONSET SEIZURE; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SALARY; SHORT TERM DISABILITY; WORKMAN COMPENSATION;

ADOLESCENT; ADULT; AGED; AMINES; ANTICONVULSANTS; COHORT STUDIES; CYCLOHEXANECARBOXYLIC ACIDS; DATABASES, FACTUAL; DRUG COSTS; EPILEPSIES, PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SICK LEAVE; WORKERS' COMPENSATION; YOUNG ADULT;

EID: 84868301197     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.04.019     Document Type: Article

References (38)

1. Anhut H., Ashman P., Feuerstein T.J., Sauermann W., Saunders M., Schmidt B. Gabapentin (neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994, 35(4):795-801.
2. Arain A.M. Pregabalin in the management of partial epilepsy. Neuropsychiatr. Dis. Treat. 2009, 5:407-413.
3. Arroyo S., Anhut H., Kugler A.R., Lee C.M., Knapp L.E., Garofalo E.A., Messmer S. Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004, 45(1):20-27.
4. Beghi E., Atzeni L., Garattini L. Economic analysis of newer antiepileptic drugs. CNS Drugs 2008, 22(10):861-875.
5. Begley C.E., Famulari M., Annegers J.F., Lairson D.R., Reynolds T.F., Coan S., Dubinsky S., Newmark M.E., Leibson C., So E.L., Rocca W.A. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000, 41(3):342-351.
6. Beydoun A., Uthman B.M., Kugler A.R., Greiner M.J., Knapp L.E., Garofalo E.A. Pregabalin 1008-009 Study Group. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005, 64(3):475-480.
7. Blough D.K., Madden C.W., Hornbrook M.C. Modeling risk using generalized linear models. J. Health Econ. 1999, 18(2):153-171.
8. Bockbrader H.N., Wesche D., Miller R., Chapel S., Janiczek N., Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin. Pharmacokinet. 2010, 49(10):661-669.
9. Brodie M.J. Antiepileptic drug therapy the story so far. Seizure 2010, 19(10):650-655.
10. Bureau of Labor Statistics Consumer Price Index: All Urban Consumers (Current Series) 2012, Bureau of Labor Statistics, United States Department of Labor, Available at: http://data.bls.gov/PDQ/outside.jsp?survey=cu (accessed January 16, 2012).
11. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987, 40:373-383.
12. Delahoy P., Thompson S., Marschner I.C. Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships. BMC Neurol. 2010, 10(104).
13. Elger C.E., Brodie M.J., Anhut H., Lee C.M., Barrett J.A. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005, 46(12):1926-1936.
14. Elliott J.O., Lu B., Shneker B., Charyton C., Layne J., Moore Comorbidity, health screening, and quality of life among persons with a history of epilepsy. Epilepsy Behav. 2009, 14(1):125-129.
15. Epilepsy Foundation Incidence and Prevalence. Epilepsy Foundation Website 2010, Available at: http://www.epilepsyfoundation.org/aboutepilepsy/whatisepilepsy/statistics.cfm (accessed December 14, 2011).
16. Epilepsy Foundation Partial Seizures. Epilepsy Foundation Website 2010, Available at: http://www.epilepsyfoundation.org/aboutepilepsy/seizures/partialseizures/index.cfm (accessed December 14, 2011).
17. French J.A., Faught E. Rational polytherapy. Epilepsia 2009, 50(Suppl. 8):63-68.
18. French J.A., Kugler A.R., Robbins J.L., Knapp L.E., Garofalo E.A. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003, 60(10):1631-1637.
19. Gore M., Sadosky A., Leslie D., Tai K.-S., Seleznick M. Patterns of therapy switching, augmentation and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin. Ther. 2012, 33(12):1914-1931.
20. Gore M., Tai K.S., Zlateva G., Bala Chandran A., Leslie D. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. Pain Pract. 2011, 11(6):528-539.
21. Gore M., Sadosky A.B., Zlateva G., Clauw D.J. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract. 2009, 9(5):363-374.
22. Gore M., Sadosky A., Tai K.S., Stacey B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin. Ther. 2007, 29(8):1655-1670.
23. Ivanova J.I., Birnbaum H.G., Kidolezi Y., Qiu Y., Mallett D., Caleo S. Economic burden of epilepsy among the privately insured in the US. Pharmacoeconomics 2010, 28(8):675-685.
24. Ivanova J.I., Birnbaum H.G., Kidolezi Y., Qiu Y., Mallett D., Caleo S. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia 2010, 51(5):838-844.
25. Kanner A.M. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol. Psychiatry 2003, 54(3):388-398.
26. LaRoche S.M. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist 2007, 13(3):133-139.
27. Leidy N.K., Elixhauser A., Vickrey B., Means E., Willian M.K. Seizure frequency and the health-related quality of life of adults with epilepsy. Neurology 1999, 53(1):162-166.
28. Lhatoo S.D., Wong I.C., Polizzi G., Sander J.W. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 2000, 41(12):1592-1596.
29. Lyrica Package Insert 2011, Pfizer Inc., New York, NY.
30. Murray M.I., Halpern M.T., Leppik I.E. Cost of refractory epilepsy in adults in the USA. Epilepsy Res. 1996, 23(2):139-148.
31. Neurontin Package Insert 2011, Pfizer Inc., New York, NY.
32. Sivenius J., Kälviäinen R., Ylinen A., Riekkinen P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991, 32(4):539-542.
33. Tellez-Zenteno J.F., Patten S.B., Jetté N., Williams J., Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007, 48(12):2336-2344.
34. Udall M., Harnett J., Mardekian J. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. J. Med. Econ. 2012, 15(2):1-10.
35. UK Gabapentin Study Group Gabapentin in partial epilepsy. Lancet 1990, 335(8698):1114-1117.
36. US Gabapentin Study Group No.5 Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993, 43(11):2292-2298.
37. Yuen A.W., Singh R., Bell G.S., Bhattacharjee A., Neligan A., Heaney D.C., Duncan J.S., Sander J.W. The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre. Epilepsy Res. 2009, 87(2-3):120-123.
38. Zeber J.E., Copeland L.A., Pugh M.J. Variation in antiepileptic drug adherence among older patients with new-onset epilepsy. Ann. Pharmacother. 2010, 44(12):1896-1904.